Abstract Body

Rapid access to antiretroviral therapy (ART) immediately following HIV testing is upheld as a prevention tool to reduce HIV transmission and improve outcomes along the HIV care continuum. In 2016, the Miami-Dade County Health Department launched a test and treat (T&T) initiative to offer same-day or next-day access to ART following initial HIV diagnosis. This study aims to evaluate HIV care outcomes, including viral load (VL) suppression (<200 copies/mL) and retention in HIV care (two or more HIV-related labs, medical visits or prescriptions at least three months apart), for persons whose HIV was diagnosed in Miami-Dade County in 2017.

Clinical and epidemiological data reported to the Florida Department of Health HIV/AIDS surveillance system were matched to lab, medical visit and prescription records in Ryan White Program databases, county health department electronic health records and Medicaid claims. HIV care outcomes among antiretroviral-naïve patients whose initial HIV diagnosis was in Miami-Dade County in 2017 and who engaged in HIV care (n=950), including patients in T&T (n=80), were evaluated to determine the impact of T&T.

T&T did not significantly impact the rate of HIV care initiation within 30 days of diagnosis (85.0% vs. 81.5%). However, patients in T&T were more likely to achieve VL suppression within six months of diagnosis (87.5% vs. 66.1%, p<0.01) and be retained in care (91.3% vs. 81.6%, p=0.03). For patients with a suppressed VL within six months of diagnosis, the average number of days from diagnosis to VL suppression was lower for T&T (71 vs. 87, p<0.01). When evaluating patients retained in care, higher rates of VL suppression (90.4% vs. 76.1%, p<0.01) and more rapid VL suppression (72 vs. 89 days, p<0.01) persisted for T&T. Furthermore, patients in T&T were more likely to receive HIV resistance testing within three months of diagnosis (80.0% vs. 57.8%, p<0.01).

While T&T did not significantly impact the timing of HIV care initiation, patients in T&T were more likely to achieve VL suppression within six months of diagnosis and progress to VL suppression more rapidly. Patients in T&T were also more likely to receive a baseline HIV resistance test, indicating a complete initial HIV care assessment. Rapid access to ART following HIV diagnosis can help reduce HIV-related mortality, improve health outcomes of those living with HIV and reduce HIV transmission through VL suppression.